Tyrosinemia (or "Tyrosinaemia") is an error of metabolism, usually inborn, in which the body can not effectively break down the amino acid tyrosine, found in most animal and plant proteins. Tyrosinemia is inherited in an autosomal recessive pattern. There are three types of tyrosinemia, each with distinctive symptoms and caused by the deficiency of a different enzyme.
Types
Type I tyrosinemia
Type I tyrosinemia () is the most severe form of this disorder and is caused by a shortage of the
enzyme fumarylacetoacetate hydrolase (), encoded by the gene
FAH. Fumarylacetoacetate hydrolase is the last in a series of five enzymes needed to break down tyrosine. Symptoms of type I tyrosinemia usually appear in the first few months of life and include failure to gain weight and grow at the expected rate (failure to thrive), diarrhea, vomiting, yellowing of the skin and whites of the eyes (
jaundice), cabbagelike odor, and increased tendency to bleed (particularly
nosebleeds). Type I tyrosinemia can lead to
liver and
kidney failure, problems affecting the
nervous system, and an increased risk of
liver cancer.
Worldwide, type I tyrosinemia affects about 1 person in 100,000. This type of tyrosinemia is much more common in Quebec, Canada. The overall incidence in Quebec is about 1 in 16,000 individuals. In the Saguenay-Lac St. Jean region of Quebec, type 1 tyrosinemia affects 1 person in 1,846.
Type II tyrosinemia
Type II tyrosinemia () is caused by a deficiency of the enzyme
tyrosine aminotransferase (), encoded by the gene
TAT. Tyrosine aminotransferase is the first in a series of five enzymes that converts tyrosine to smaller molecules, which are excreted by the kidneys or used in reactions that produce energy. This form of the disorder can affect the
eyes,
skin, and mental development. Symptoms often begin in early childhood and include excessive tearing, abnormal sensitivity to light (
photophobia), eye pain and redness, and painful skin lesions on the palms and soles. About half of individuals with type II tyrosinemia are also mentally retarded. Type II tyrosinemia occurs in fewer than 1 in 250,000 individuals.
Type III tyrosinemia
Type III tyrosinemia () is a rare disorder caused by a deficiency of the enzyme
4-hydroxyphenylpyruvate dioxygenase (), encoded by the gene
HPD. This enzyme is abundant in the liver, and smaller amounts are found in the kidneys. It is one of a series of enzymes needed to break down tyrosine. Specifically, 4-hydroxyphenylpyruvate dioxygenase converts a tyrosine byproduct called 4-hydroxyphenylpyruvate to homogentisic acid. Characteristic features of type III tyrosinemia include mild
mental retardation,
seizures, and periodic loss of balance and coordination (
intermittent ataxia). Type III tyrosinemia is very rare; only a few cases have been reported.
Treatment
Treatment varies depending on the specific type. A low
protein diet may be required in the management of tyrosinemia.
See also
External links
Genetic disorders | Inborn errors of metabolism
Tyrozynemia